% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
%
\documentclass[
  ignorenonframetext,
  twocolumn]{beamer}
\usepackage{pgfpages}
\setbeamertemplate{caption}[numbered]
\setbeamertemplate{caption label separator}{: }
\setbeamercolor{caption name}{fg=normal text.fg}
\beamertemplatenavigationsymbolsempty
% Prevent slide breaks in the middle of a paragraph
\widowpenalties 1 10000
\raggedbottom
\setbeamertemplate{part page}{
  \centering
  \begin{beamercolorbox}[sep=16pt,center]{part title}
    \usebeamerfont{part title}\insertpart\par
  \end{beamercolorbox}
}
\setbeamertemplate{section page}{
  \centering
  \begin{beamercolorbox}[sep=12pt,center]{part title}
    \usebeamerfont{section title}\insertsection\par
  \end{beamercolorbox}
}
\setbeamertemplate{subsection page}{
  \centering
  \begin{beamercolorbox}[sep=8pt,center]{part title}
    \usebeamerfont{subsection title}\insertsubsection\par
  \end{beamercolorbox}
}
\AtBeginPart{
  \frame{\partpage}
}
\AtBeginSection{
  \ifbibliography
  \else
    \frame{\sectionpage}
  \fi
}
\AtBeginSubsection{
  \frame{\subsectionpage}
}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\makeatletter
\@ifundefined{KOMAClassName}{% if non-KOMA class
  \IfFileExists{parskip.sty}{%
    \usepackage{parskip}
  }{% else
    \setlength{\parindent}{0pt}
    \setlength{\parskip}{6pt plus 2pt minus 1pt}}
}{% if KOMA class
  \KOMAoptions{parskip=half}}
\makeatother
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  pdftitle={GLP-1 Receptor Agonists and effects on dementia among diabetes patients in Denmark: an analysis of synthetic data},
  pdfauthor={Nerissa Nance, BBD Capstone Project},
  hidelinks,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\newif\ifbibliography
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{-\maxdimen} % remove section numbering
\renewcommand{\tightlist}{\setlength{\itemsep}{2ex}\setlength{\parskip}{0pt}}

\title{GLP-1 Receptor Agonists and effects on dementia among diabetes
patients in Denmark: an analysis of synthetic data}
\author{Nerissa Nance, BBD Capstone Project}
\date{May 6, 2021}

\begin{document}
\frame{\titlepage}

\begin{frame}{Motivation}
\protect\hypertarget{motivation}{}
\begin{itemize}
\tightlist
\item
  Type 2 diabetes mellitus (T2DM) is a cardiometabolic disease affecting
  over 6\% of the global population, and 15-20\% of the global
  population of those over the age of 50 as of 2017 (and trending
  upward) (Khan et al.~2020; Lin et al.~2020)
\item
  Increasing evidence has linked T2DM to dementia (Campbell et al.~2018;
  Huang 2016)
\item
  Control of diabetes is generally addressed using first-line
  medications (namely metformin), but second-line regimes (such as GLP-1
  receptor agonists/GLP-1RA or SGLT2 inhibitors) are increasingly used
  as well
\item
  There is substantial evidence that diabetes medication, including
  second line regimes like GLP-1, can decrease dementia risk (Duarte et
  al.~2013; Wu et al.~2020)
\end{itemize}
\end{frame}

\begin{frame}{Motivation}
\protect\hypertarget{motivation-1}{}
\begin{itemize}
\tightlist
\item
  GLP-1RAs are a relatively new treatment for diabetes; some forms have
  been ion the market since 2005, others as recently as 2013 (White
  2015)
\item
  There is reason to believe that GLP-1 is particularly neuroprotective
  (Duarte et al.~2013), but most studies have been associational and
  have not compared head-to-head with other second-line regimes; causal
  analysis is warranted
\end{itemize}

\begin{center}\includegraphics[width=0.6\linewidth,height=0.5\textheight]{glp1_image} \end{center}
\end{frame}

\begin{frame}{Causal question}
\protect\hypertarget{causal-question}{}
What is the effect of cumulative exposure to GLP-1RAs vs.~active
comparator (other second line, SLGT2i) on dementia?
\end{frame}

\begin{frame}{Structural causal model (the point-treatment case)}
\protect\hypertarget{structural-causal-model-the-point-treatment-case}{}
\begin{center}\includegraphics[width=0.9\linewidth,height=0.8\textheight]{ggdag1} \end{center}
\end{frame}

\begin{frame}{Structural causal model (the longitudinal case)}
\protect\hypertarget{structural-causal-model-the-longitudinal-case}{}
\begin{center}\includegraphics[width=0.9\linewidth,height=0.8\textheight]{ggdag2} \end{center}
\end{frame}

\begin{frame}{Structural causal model}
\protect\hypertarget{structural-causal-model}{}
\begin{columns}[T]
\begin{column}{0.48\textwidth}
\[O = (L_0, A_0, ..., A_t, L_t, Y_t)  \approx P_0 \]

Where \(t = 1,...,9\) in 6-month follow-up intervals

\(A_t\) = exposure to GLP-1RAs at time t

\(Y_t\) = onset of dementia at time t
\end{column}

\begin{column}{0.48\textwidth}
\(L_t\) =

\begin{itemize}
  \item Age (time-constant)
  \item Sex (time-constant)
  \item Renal disease onset at time t (time-varying)
  \item Obesity status at time t (time-varying)
  \item Time-varying blood glucose (time-varying)
  \item Time-varying cholesterol (time-varying)
\end{itemize}
\end{column}
\end{columns}
\end{frame}

\begin{frame}{Target trial and counterfactual}
\protect\hypertarget{target-trial-and-counterfactual}{}
In our ideal experiment we would enroll T2DM patients who are:

\begin{itemize}
\tightlist
\item
  over 40 years old;
\item
  have least five years on a first-line treatment;
\item
  are beginning a second line treatment (namely GLP-1 or SGLT2i) for the
  first time.
\end{itemize}

Causal quantity:

\(Y_{\bar{a}} = f_Y(\bar{L}(t),\bar{a}(t), U_{Y})\), where
\(\bar{a} \in {0,1}\) and denotes the counterfactual exposure history.
\end{frame}

\begin{frame}{Intervention on the SCM}
\protect\hypertarget{intervention-on-the-scm}{}
How would expected dementia risk have differed if all subjects had used
GLP-1RAs throughout follow up vs.~if they used SLGT2i throughout follow
up?

\[ E(Y_{\bar{a}=1}-Y_{\bar{a}=0}) \]
\end{frame}

\begin{frame}{Observed data and link to causal model}
\protect\hypertarget{observed-data-and-link-to-causal-model}{}
We will emulate our target trial using observational data from an
expansive cohort of over 42,000 Danish diabetes patients beginning a
second-line regime after 2015.

\begin{center}\includegraphics[width=0.75\linewidth]{consort} \end{center}

Due to Danish registry access issues, for the purposes of this analysis
we used simulated data.
\end{frame}

\begin{frame}{Simulations}
\protect\hypertarget{simulations}{}
\begin{itemize}
\tightlist
\item
  We simulated the data by drawing samples from the discrete
  multivariate probability distributions of our X variables from Danish
  Registry summary statistics
\item
  Exposure and time-varying confounder data were aggregated into
  discrete classes for simplicity and data privacy
\item
  Other univariate distributions were known but not included in the
  current analysis because without the multivariate distribution that
  includes other X variables, these variables would only add noise to
  the estimation
\end{itemize}
\end{frame}

\begin{frame}{Table 1: Baseline covariates by baseline GLP-1 use in
simulated data}
\protect\hypertarget{table-1-baseline-covariates-by-baseline-glp-1-use-in-simulated-data}{}
\begin{tabular}[t]{l|l|l|l}
\hline
  & 0 & 1 & p\\
\hline
n & 21438 & 23562 & \\
\hline
Age (\%) &  &  & <0.001\\
\hline
41-50 & 47 ( 0.2) & 37 ( 0.2) & \\
\hline
51-60 & 8415 (39.3) & 8609 (36.5) & \\
\hline
61-70 & 8932 (41.7) & 10339 (43.9) & \\
\hline
71-80 & 3779 (17.6) & 4363 (18.5) & \\
\hline
81-90 & 265 ( 1.2) & 214 ( 0.9) & \\
\hline
Sex = Male (\%) & 13374 (62.4) & 13902 (59.0) & <0.001\\
\hline
BL kidney disease = 1 (\%) & 84 ( 0.4) & 87 ( 0.4) & 0.755\\
\hline
BL obesity = 1 (\%) & 7505 (35.0) & 8090 (34.3) & 0.137\\
\hline
\end{tabular}
\end{frame}

\begin{frame}{A review of the statistical model and estimand (point
treatment)}
\protect\hypertarget{a-review-of-the-statistical-model-and-estimand-point-treatment}{}
Target parameter is the average treatment effect (ATE):

\[\Psi(P_0) = E_W[E_0(Y|A=1,W) - E(Y|A=0,W)]\]

Under the randomization and positivity assumptions, one way to estimate
this is through the G-Computation formula:
\[\hat{\Psi}(P_n) = E(Y_a) = \sum_w E_0(Y|A=a,W=w)P_0(W=w)\]
\end{frame}

\begin{frame}{The longitudinal case}
\protect\hypertarget{the-longitudinal-case}{}
Time-dependent confounding complicates our ability to estimate the ATE

\begin{center}\includegraphics[width=0.75\linewidth]{identifiability} \end{center}

\begin{itemize}
\tightlist
\item
  if we adjust for L naively, we lose the effect of A(1) through L(2),
  we can't stratify on descendants of A
\end{itemize}

\ldots what to do?
\end{frame}

\begin{frame}{Statistical model and estimand for longitudinal data}
\protect\hypertarget{statistical-model-and-estimand-for-longitudinal-data}{}
We want to estimate the ATE of the counterfactual treatment histories
(\(\bar{a}\)) of continuously exposed to GLP-1 (\(\bar{a}=1\)) and
continously exposed to SGLT2i (\(\bar{a}=0\)):

\[ E(Y_{\bar{a}=1}-Y_{\bar{a}=0}) \]

To account for the time-dependent nature of the confounding variables,
we used longitudinal estimators.
\end{frame}

\begin{frame}{Longitudinal conterfactual estimators}
\protect\hypertarget{longitudinal-conterfactual-estimators}{}
In longitudinal target parameters, we must evaluate them such that we do
not condition on descendants of our treatment node.

In the case of G-Comp, one way to side step this is through a series of
conditional expectations:

\[E_{P\bar{a}}(Y_{\bar{a}}) = E(E(...E(E(Y_{\bar{a}}|\bar{L}_{\bar{a}}(K))|\bar{L}_{\bar{a}}(K-1))...|L(1)))\]

Where \[\bar{L}_{\bar{a}} \equiv \bar{L}(K),\bar{A}(K)\]
\end{frame}

\begin{frame}{Longitudinal conterfactual estimators}
\protect\hypertarget{longitudinal-conterfactual-estimators-1}{}
I don't know about you, but for it was helpful to look at a two
time-unit example:

\[E( E( E(Y|A(2)=1,A(1)=1,L(2),L(1))|A(1)=1,L(1)))\]

Summing over the covariate distributions\ldots{} \small
\[\sum_{l(1)}  \left[ \sum_{l(2)}E(Y|\bar{L}=\bar{l},\bar{A}=1)P(L(2)=l(2)|A(1)=1,L(1)=l(1)\right]P(L(1)=l(1))\]
\normalsize
\end{frame}

\begin{frame}{A note on identifiability in longitudinal data}
\protect\hypertarget{a-note-on-identifiability-in-longitudinal-data}{}
\begin{itemize}
\tightlist
\item
  In longitudinal analyses, time-dependent confounding makes
  identifiability more complicated.
\end{itemize}

We must assess independence sequentially: \[
Y_{\bar{a}} \perp \!\!\! \perp A(t) | \bar{L}(t), \bar{A}(t-1)
\]

This is called the sequential randomization assumption, analog to the
point-treatment randomization assumption, which we will assume is met
for the purpose of this analysis.
\end{frame}

\begin{frame}{Analysis}
\protect\hypertarget{analysis}{}
After smoothing over 6-month gaps of GLP-1 and SGLT2i exposure, we
constrasted dementia outcomes between T2DM patients with continuous
GLP-1 exposure and T2DM patients with continuous SGLT2i exposure.

We used the l-TMLE package to estimate the target parameters of interest
(GComp, IPTW, TMLE).

For the purposes of the project we used a simplified SuperLearner list
that included only SL.mean, SL.glm, SL.glmnet.
\end{frame}

\begin{frame}{Preliminary results}
\protect\hypertarget{preliminary-results}{}
\begin{center}\includegraphics[width=0.9\linewidth,height=0.75\textheight]{forestplot} \end{center}
\end{frame}

\begin{frame}{Preliminary results}
\protect\hypertarget{preliminary-results-1}{}
\begin{itemize}
\item
  We found a 0.15\% (95\% CI -0.23\%, -0.01\%) decrease in the risk of
  disease among GLP-1 users compared to SGLT2i users
\item
  Under sequential randomization and positivity assumptions, we can
  interpret this result causally:
\end{itemize}

\emph{The risk of dementia was 0.15\% lower under an intervention in
which all diabetes patients used GLP-1RAs, compared to an intervention
in which they all used SGLT2i.}
\end{frame}

\begin{frame}{Causal assumptions in context}
\protect\hypertarget{causal-assumptions-in-context}{}
\begin{itemize}
\tightlist
\item
  Unfortunately, our ability to causally interpret the parameter is
  weakened by the unmeasured confounding.
\item
  We have limited access to vital sign and lab data on only a subsample
  of Danish regions, which may lead to time-dependent confounding by
  time-varying blood glucose (or other relevant biomarkers such as
  cholesterol or blood pressure).
\item
  We will address this in future by performing sensivitiy analyses
  restricting to areas in which biomarker data is available.
\end{itemize}
\end{frame}

\begin{frame}{Discussion}
\protect\hypertarget{discussion}{}
\begin{itemize}
\tightlist
\item
  In our simulated data set with a limited covariate set, we found small
  but significant differences in dementia risk between GLP-1 users and
  SGLT2i users
\item
  While the effect is small, in the context of the population of over
  217,000 diabetes patients; an intervention on the population would
  prevent 325 cases of dementia
\item
  Further analysis will be needed, including replication on the actual
  registry data
\end{itemize}
\end{frame}

\begin{frame}{Future directions}
\protect\hypertarget{future-directions}{}
This is an admittedly limited first analysis, and we plan to expand by:

\begin{itemize}
\tightlist
\item
  Improving candidate learners
\item
  Examining additional second line treatments (eg. DPP4)
\item
  Allowing for dynamic treatment regimes
\item
  Using continuous time TMLE
\item
  Testing for robustness of the estimate across repeated simulations of
  the data
\item
  Examining additional outcomes (death, cardiovascular disease)
\item
  Running on the real data!
\end{itemize}
\end{frame}

\begin{frame}{Acknowledgements}
\protect\hypertarget{acknowledgements}{}
This (ongoing) analysis is part of a broader collaboration with Novo
Nordisk and the University of Copenhagen to advance best practices for
applying causal inference methods to real world health datasets in order
to improve patient care.

Thank you to Andrew Mertens (UC Berkeley) for his help with the data
simulations and his feedback on this presentation, and to Thomas Gerds
(University of Copenhagen) for the descriptive statistics used in the
simulations. And to the rest of the study team, including (but certainly
not limited to):

\begin{itemize}
\tightlist
\item
  Mark van der Laan, Maya Petersen (UC Berkeley)
\item
  Theis Lange, Helene Rytgaard (University of Copenhagen)
\item
  Kajsa Kvist, Trine Abrahamsen (Novo Nordisk)
\end{itemize}
\end{frame}

\begin{frame}{References (1)}
\protect\hypertarget{references-1}{}
\small

Petersen, M. Advanced Causal Inference PH252E. Lecture 3: Causal Models
and Counterfactuals. UC Berkeley (2018).

Petersen, M. Advanced Causal Inference PH252E. Lecture 7: Sequential
Regression G Computation Estimator; Longitduinal TMLE. UC Berkeley
(2018).

Campbell JM, Stephenson MD, Courten BD, Chapman I, Bellman SM,
Aromataris E. Metformin use associated with reduced risk of dementia in
patients with diabetes: a systematic review and meta-analysis. J
Alzheimers Dis. 2018;65:1225-1236

Duarte, A. I., et al.~``Crosstalk between diabetes and brain:
glucagon-like peptide-1 mimetics as a promising therapy against
neurodegeneration.'' Biochimica et Biophysica Acta (BBA)-Molecular Basis
of Disease 1832.4 (2013): 527-541.

Huang ES. Management of diabetes mellitus in older people with
comorbidities. BMJ 2016; 353: i2200.
\end{frame}

\begin{frame}{Reference (2)}
\protect\hypertarget{reference-2}{}
\small

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J.
Epidemiology of Type 2 Diabetes - Global Burden of Disease and
Forecasted Trends. J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi:
10.2991/jegh.k.191028.001. PMID: 32175717; PMCID: PMC7310804.

Lin, X., Xu, Y., Pan, X. et al.~Global, regional, and national burden
and trend of diabetes in 195 countries and territories: an analysis from
1990 to 2025. Sci Rep 10, 14790 (2020).
\url{https://doi.org/10.1038/s41598-020-71908-9}

White, John R. ``A brief history of the development of diabetes
medications.'' Diabetes Spectrum 27.2 (2014): 82-86.

Wu, Cheâ€Yuan, et al.~``Relationships between memory decline and the use
of metformin or DPP4 inhibitors in people with type 2 diabetes with
normal cognition or Alzheimer's disease, and the role APOE carrier
status.'' Alzheimer's \& Dementia 16.12 (2020): 1663-1673.
\end{frame}

\end{document}
